Delayed puberty cost-effectiveness of therapy: Difference between revisions
No edit summary |
|||
| Line 121: | Line 121: | ||
|$ 45,156 | |$ 45,156 | ||
|} | |} | ||
* General economic burden, | * General economic burden, consists of [[pharmacy]] costs, [[physician]] costs, and [[laboratory]] and [[Radiological|radiologic]] tests costs were measured as following: | ||
** [[GH]] cost per milligram, $52 | ** [[GH]] cost per milligram, $52 | ||
** Cost of [[physician]] visit, $58 | ** Cost of [[physician]] visit, $58 | ||
Revision as of 17:51, 14 September 2017
|
Delayed puberty Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Delayed puberty cost-effectiveness of therapy On the Web |
|
American Roentgen Ray Society Images of Delayed puberty cost-effectiveness of therapy |
|
Risk calculators and risk factors for Delayed puberty cost-effectiveness of therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Eiman Ghaffarpasand, M.D. [2]
Overview
There are limited data about cost-effectiveness of therapy in delayed puberty. The main part of the economic burden of delayed puberty is because of its various and specific blood tests, such as hormone assay. The main treatment for the patients with short stature is growth hormone (GH). The potential cost of treating all eligible children with growth hormone (GH) is approximately $40 billion dollars.
Cost-Effectiveness of Therapy
- There are limited data about cost-effectiveness of therapy in delayed puberty.
- The main part of the economic burden of delayed puberty is because of its various and specific blood tests, such as hormone assay.
- The main treatment for the patients with short stature is growth hormone (GH).
Delayed puberty diagnostic laboratory tests
- The brief definition of various hormone laboratory tests that maybe used for diagnosis of delayed puberty is presented here.[1]
| Laboratory test | Cost (USD) |
|---|---|
| Follicle stimulating hormone (FSH) | $ 57 |
| Luteinizing hormone (LH) | $ 57 |
| Estradiol | $ 46 |
| Testosterone | $ 58 |
| Prolactin | $ 48 |
| Human gonadotropic hormone (hCG), beta sub-unit (quantitative) | $ 44 |
| Thyroid function tests (TSH, T4, T3, T3RU) | $ 57 |
| Gonadotropin releasing hormone (GnRH) | $ 322 |
Growth hormone therapy
- General cost of GH treatment for every child (cost per child), the average height improvement in every child (growth per child), and measured cost of every inches the children have gained (cost per inches) are presented here.[2]
| Group | Variable | Cost per child
(USD) |
Growth per child
(in.) |
Cost per inches
(USD) |
|---|---|---|---|---|
| Efficacy | Lower (1.8 in) | $ 99,959 | 1.2 | $ 81,875 |
| Higher (3.9 in) | $ 99,959 | 2.6 | $ 38,783 | |
| Age at initiation | 8-13 years of age | $ 81,268 | 1.9 | $ 42,792 |
| 12-16 years of age | $ 126,123 | 1.9 | $ 66,411 | |
| Discontinuation rate | 0% | $ 137,779 | 2.6 | $ 53,531 |
| 40% | $ 87,352 | 1.7 | $ 52,174 | |
| Dosing | Low dose (0.24 mg/kg/week) | $ 65,092 | 1.4 | $ 45,700 |
| Standard dose (0.37 mg/kg/week) for 2 years
then High dosage (0.7 mg/kg/week) at puberty for 3 years |
$ 155,440 | 3.1 | $ 49,821 | |
| Standard dose (0.37 mg/kg/week) for 1 years
then High dosage (0.7 mg/kg/week) at puberty for 4 years |
$ 170,866 | 3.4 | $ 50,384 | |
| Treatment duration | 7 years (age 8-15 years old) | $ 122,513 | 2.5 | $ 49,396 |
| 10 years (age 5-15 years old) | $ 145,550 | 3.2 | $ 45,156 |
- General economic burden, consists of pharmacy costs, physician costs, and laboratory and radiologic tests costs were measured as following:
- GH cost per milligram, $52
- Cost of physician visit, $58
- Bone-age radiograph, $17
- Free thyroxine and thyrotropin measurement, $74
- Insulin-like growth factor I determination, $27.[2]
References
- ↑ Blondell RD, Foster MB, Dave KC (1999). "Disorders of puberty". Am Fam Physician. 60 (1): 209–18, 223–4. PMID 10414639.
- ↑ 2.0 2.1 Lee, Joyce M.; Davis, Matthew M.; Clark, Sarah J.; Hofer, Timothy P.; Kemper, Alex R. (2006). "Estimated Cost-effectiveness of Growth Hormone Therapy for Idiopathic Short Stature". Archives of Pediatrics & Adolescent Medicine. 160 (3): 263. doi:10.1001/archpedi.160.3.263. ISSN 1072-4710.